Skip to main content
Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc. — Investor Relations & Filings

Ticker · CLRB ISIN · US15117F8077 LEI · 5493000NFZCRG7BYQV93 US Manufacturing
Open in API
Filings indexed 1,033 across all filing types
Latest filing 2011-12-07 Capital/Financing Update
Country US United States of America
Listing US CLRB

About Cellectar Biosciences, Inc.

https://www.cellectar.com/

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted cancer treatments. The company's core technology is a proprietary Phospholipid Drug Conjugate (PDC) platform that selectively delivers therapeutic payloads, such as radioisotopes and cytotoxins, to cancer cells by targeting lipid rafts in their plasma membranes. This approach is designed to maximize antitumor activity while minimizing off-target effects on healthy tissue. Cellectar's lead product candidate is iopofosine I 131, a first-in-class PDC that delivers the radioisotope iodine-131. It is being developed for the treatment of hematologic malignancies and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Waldenstrom's Macroglobulinemia.

Recent filings

Filing Released Lang Actions
PROSPECTUS
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(3), describing the issuance and sale of units consisting of common stock and warrants. It details underwriting agreements, offering price, and terms of the securities. This type of document is related to capital raising activities and financing updates. It is not an annual report, earnings release, or management discussion. The document length is under 5,000 characters and is a detailed supplement to a prospectus, which fits the Capital/Financing Update category rather than a full prospectus or registration statement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2011-12-07 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 7, 2011, reporting the entry into a material definitive agreement related to an underwriting agreement for a public offering of units consisting of common stock and warrants. It includes details about the offering price, number of units, and terms of the warrants. The document also references a press release about closing the public offering. The content focuses on financing activities, specifically the issuance and sale of securities and related agreements. There are no financial statements or quarterly/yearly financial results presented, so it is not an earnings release or annual/interim report. The primary subject is a capital raising event and related agreements, which fits the Capital/Financing Update category.
2011-12-07 English
FORM 424B1
Capital/Financing Update Classification · 100% confidence The document is a Form 424B1 prospectus filed pursuant to Rule 424(b)(1), which is a type of prospectus used in public offerings of securities. It details a firm commitment public offering of units consisting of common stock and warrants, including pricing, underwriting discounts, use of proceeds, risk factors, and other offering details. The document includes extensive information about the offering, the company's business, management discussion, financial statements, and legal matters. This type of document is a capital raising disclosure related to financing activities, not a financial report, earnings release, or management discussion standalone. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (15,000 characters) and detailed offering information confirm it is not merely an announcement or a short notice but a full prospectus related to capital raising.
2011-12-02 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated December 1, 2011. It announces that the company issued a press release titled "Novelos Therapeutics Prices $5.9 Million Public Offering." The content focuses on a financing event (public offering) and includes the press release as an exhibit. The document length is short (2501 characters), and it primarily serves as an announcement of a capital raising event. There are no financial statements or detailed financial data included. Therefore, this filing is best classified as a Capital/Financing Update (CAP).
2011-12-01 English
Regulatory Filings 2011
Regulatory Filings
2011-12-01 English
Capital/Financing Update 2011
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the SEC Division of Corporation Finance regarding the acceleration of the effective date of a Registration Statement on Form S-1 for Novelos Therapeutics, Inc. It references distribution of a Preliminary Prospectus and compliance with SEC rules related to securities offerings. The document is short (1798 characters) and is clearly an announcement or correspondence related to a capital raising process, specifically the registration and offering of securities. It does not contain financial statements or detailed financial data, nor is it a full report. This fits the category of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2011-11-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.